Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -43.14% is 30% below its 1-year average of -33.15%, near the low end of its 1-year range (-43.14%–-24.13%).
As of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -43.14%.
RETURN ON EQUITY (ROE)
-43.14%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-2.69%
vs the sector median at left
Carlsmed, Inc.
Market Cap
$404.51M
Return on Equity (ROE)
-43.14%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$404.81M
Return on Equity (ROE)
-28.18%
TTM Avg
-0.06%
3Y Avg
10.58%
5Y Avg
10.58%
Market Cap
$404.05M
Return on Equity (ROE)
-80.96%
TTM Avg
-47.93%
3Y Avg
-34.61%
5Y Avg
-20.56%
Market Cap
$406.13M
Return on Equity (ROE)
-37.05%
TTM Avg
-58.80%
3Y Avg
-40.96%
5Y Avg
-32.01%
Market Cap
$407.87M
Return on Equity (ROE)
-77.06%
TTM Avg
-61.48%
3Y Avg
-56.03%
5Y Avg
-55.28%
Market Cap
$407.95M
Return on Equity (ROE)
-51.17%
TTM Avg
-29.16%
3Y Avg
-33.45%
5Y Avg
-16.04%
Market Cap
$411.43M
Return on Equity (ROE)
14.40%
TTM Avg
1.26%
3Y Avg
-7.83%
5Y Avg
-9.02%
Market Cap
$415.42M
Return on Equity (ROE)
-69.06%
TTM Avg
36.89%
3Y Avg
36.89%
5Y Avg
36.89%
Market Cap
$415.22M
Return on Equity (ROE)
-121.12%
TTM Avg
180.84%
3Y Avg
-1331.02%
5Y Avg
-839.91%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Carlsmed, Inc. (CARL) | $404.51M | -43.14% | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $404.81M | -28.18% | -0.06% | 10.58% | 10.58% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $404.05M | -80.96% | -47.93% | -34.61% | -20.56% |
| Myriad Genetics, Inc. (MYGN)vs › | $406.13M | -37.05% | -58.80% | -40.96% | -32.01% |
| Rezolute, Inc. (RZLT)vs › | $407.87M | -77.06% | -61.48% | -56.03% | -55.28% |
| Neurogene Inc. (NGNE)vs › | $407.95M | -51.17% | -29.16% | -33.45% | -16.04% |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.43M | 14.40% | 1.26% | -7.83% | -9.02% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $415.42M | -69.06% | 36.89% | 36.89% | 36.89% |
| Senseonics Holdings, Inc. (SENS)vs › | $415.22M | -121.12% | 180.84% | -1331.02% | -839.91% |
| REGENXBIO Inc. (RGNX)vs › | $393.42M | -273.72% | -138.09% | -103.75% | -71.29% |
ROE
-43.1%
ROA
-30.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -43.14% |
| 2026-03-31 | -35.34% |
| 2025-12-31 | -29.97% |
| 2025-09-30 | -24.13% |
